An organic synthesis of materials to achieve removal of low molecular weight ionic species, such as transition metal ions including cobalt, iron, nickel, and zinc, from aqueous solutions. The synthesis includes the steps of providing a cation exchange resin, functionalizing the cation exchange resin using a chloride intermediate to form a sulfonyl chloride resin, and reacting a multi-amine based ligand with the sulfonyl chloride resin to form a sequestration resin. The synthesis further includes the steps of cooling the sequestration resin, and washing and drying the sequestration resin.

An exemplary system for treatment and disposal of pharmaceutical waste comprises a sealable pail, a stirring device, a sealable bag, a container, an acidic substance, and a denaturant. The sealable pail receives the pharmaceutical waste and the acidic substance. The acidic substance dissolves the pharmaceutical waste, and the stirring device stirs the acidic substance to ensure that the pharmaceutical waste is completely dissolved. The denaturant is added to the dissolved pharmaceutical waste and renders the dissolved pharmaceutical waste safe for transport. The treated pharmaceutical waste is sealed within the sealable pail, and the sealable bag receives the sealed pail and is sealed. The sealed bag is then placed in the container for transport to a disposal facility.

Techniques for disposing of one or more toxic materials, such as coal waste (e.g., fly ash, sludge, etc.), include incorporating the toxic materials into artificial feldspar or forming artificial feldspar from the toxic material(s). The artificial feldspar may be used to form an artificial aggregate, which may be used in a construction material, as road base, as a fill material or for any other suitable purpose. Artificial aggregates that are formed from toxic materials are also disclosed, as are construction materials that include such artificial aggregates.

A treatment system and a method for removal of at least one halogenated compound, such as PCBs, found in contaminated systems are provided. The treatment system includes a polymer blanket for receiving at least one non-polar solvent. The halogenated compound permeates into or through a wall of the polymer blanket where it is solubilized with at least one non-polar solvent received by said polymer blanket forming a halogenated solvent mixture. This treatment system and method provides for the in situ removal of halogenated compounds from the contaminated system. In one embodiment, the halogenated solvent mixture is subjected to subsequent processes which destroy and/or degrade the halogenated compound.

An embodiment of the present invention relates to a method for treating spent caustic soda generated from an oil refinery process, a petrochemical process, etc. through a process in which a series of treatment steps are integrated, wherein the method can constitute a process under mild conditions excluding high temperature and/or high pressure conditions and can be advantageous to a post treatment process since the amount of by-products is small.

The invention relates to process for the treatment of a hydrophobic surface by a liquid film comprising an aqueous phase comprising the coating of said surface by the liquid whose aqueous phase comprises an effective amount of an agent of modification of the properties of surface and an active agent.

Compositions and methods for treating biofilm formation and growth on a substrate are provided. The composition comprises 1 ppb to 1,000 ppm of at least one D-amino acid and 1 ppm to 60,000 ppm of at least one biocide. The method comprises contacting the substrate with 1 ppb to 1,000 ppm of at least one D-amino acid and 1 ppm to 60,000 ppm of at least one biocide. The compositions and methods are effective for preventing, reducing or eliminating biofilm formation or biofilm growth or both, as well as eradicating established, recalcitrant biofilms, particularly biofilms comprising sulfate reducing bacteria that are known to cause microbiologically influenced corrosion, biofouling, or both.

The present invention relates to novel isocyanate and isothiocyanate compounds, to pharmaceutical compositions comprising them, and to the use thereof in the treatment of cancer diseases in humans and animals. The novel isocyanate and isothiocyanate compounds are distinguished, as compared with the known isocyanate and isothiocyanate compounds, by improved therapeutical breadth, i.e. fewer side effects while having high anti-tumor activity.

Alkyl nitrate ester compounds are provided for the delivery of nitric oxide to targeted muscle tissues, and in particular, to normal and dystrophic muscles. In one aspect, nitrate ester compounds are provided having the following formula: wherein, R1 is ONO2, CH2ONO2, CnH2n+1OH, CnH2n+1OH, or CH2CH2CH3, or H;R2 is ONO2, CH2ONO2, Cn'H2n'+1OH, Cn'H2n'+1OH, CH2CH2CH3 or H; andR3 is ONO2, CH2ONO2, Cn'″H2n″+1OH, Cn″H2n″+1OH, CH2CH2CH3 or H; wherein n is an integer from 0 to 9, n' is an integer from 0 to 9, and n″ is an integer from 0 to 9, and n+n'+n″≦9, and wherein at least one of R1, R2, and R3 is an ester nitrate selected from the group consisting of ONO2, CH2ONO2, and combinations thereof.

The present invention concerns a TCTP antagonist, in particular a nucleic acid targeting an m RNA encoding Translationally-Controlled Tumor Protein (TCTP), wherein said nucleic acid is capable of reducing the amount of TCTP in cells, for use in the treatment or prevention of hormone-independent cancer or chemo-resistant cancer, such as an androgen-independent prostate cancer.

Disclosed herein are methods and reagents for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) targeting treatment. The detection of these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.

A cytosine analog, a method of preparation of a cytosine analog, a DNA methyltransferase 1 inhibitor, and a method for DNA methylation inhibition, is provided for the treatment of diseases associated with deviations from normal DNA methylation. The analog of cytosine may be comprised of 1, N4, 5 and 6-substituted derivatives of cytosine or 5,6-dihydrocytosine, wherein the analog can be described by the chemical formula where R1 is H, R3, R4, 2'-deoxyribosyl, R4 is alkyl or aryl, X is N or C, wherein if X in the analog of formula I is N, then R5 is no substituent and if X in the analog of formula I and/or II is C or if X in the analog of formula II is N, then R5 and R6 are independently alkyl, aryl, hydroxyalkyl, aminoalkyl, hydroxyl, carboxyl, amino group, alkoxyl, aryloxyl, aminoalkyl, aminoaryl, thio group, sulfonyl, sulfinyl or halogen.

The present invention relates to oligomer compounds (oligomers) for the treatment and prevention of acute myeloid leukemia, which target GLI2 mRNA in a cell, leading to reduced expression of GLI2.

RNA interference is provided for inhibition of Frizzled Related Protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma.

Provided herein are compounds used to inhibit the deamination enzyme responsible for the inactivation of therapeutic compounds, and methods of using them.

Systems and methods are disclosed for evaluating cardiovascular treatment options for a patient. One method includes creating a three-dimensional model representing a portion of the patient's heart based on patient-specific data regarding a geometry of the patient's heart or vasculature; and for a plurality of treatment options for the patient's heart or vasculature, modifying at least one of the three-dimensional model and a reduced order model based on the three-dimensional model. The method also includes determining, for each of the plurality of treatment options, a value of a blood flow characteristic, by solving at least one of the modified three-dimensional model and the modified reduced order model; and identifying one of the plurality of treatment options that solves a function of at least one of: the determined blood flow characteristics of the patient's heart or vasculature, and one or more costs of each of the plurality of treatment options.

A method and system for treating brain disorders comprises detecting activity of a first target area of the brain via a first implanted sensor and determining the presence of target brain activity by analyzing the detected brain activity in combination with treating the user based upon the determined presence of target brain activity by supplying a first therapeutic agent to the first target area via a first implanted fluid delivery member including at least one distal opening adjacent to the first target area. In addition, the system may be used as well for testing the effectiveness of drugs.

The present invention relates to organometallic compounds useful in the treatment of metastasis. The organometallic compounds comprise a ligand that is covalently bound to a bioactive compound, which is an inhibitor of a resistance pathway or a derivative thereof. Preferably, the organometallic compounds are half-sandwich (“piano-stool”) compounds. The compounds of the present invention offer a high variability with respect to the bioactive compound and to the nature of the ligand bound to a central transition metal.

Bromoacetoxycalcidiol (B3CD), which is structurally related to calcidiol, exhibits cytotoxic and apoptotic activity toward cancer cells, including highly aggressive neuroblastoma cells. A series of small molecules designed around the structure of B3CD is expected to have growth inhibitory and apoptogenic activities toward a wide range of malignancies. B3CD shows no apparent toxicity in vivo, indicating potential value as a chemotherapeutic agent which will be particularly useful in treating highly aggressive tumors.

Provided are methods for the treatment of a rheumatic disease, such as rheumatoid arthritis, ankylosating spondylitis and/or polymyalgia rheumatic, by administering a delayed-release dosage form of a glucocorticoid to a subject in need thereof wherein the treatment is administered once daily for at least about two weeks. Also provided are methods for the treatment of osteoarthritis by administering a delayed-release dosage form of a glucocorticoid to a subject in need thereof wherein the treatment is administered once daily for at least about two weeks.

It is reported herein that certain muscle diseases and conditions, including forms of muscular dystrophy, are characterized by impaired insulin-dependent signaling in the muscle tissue, in essence, a form of insulin resistance. The present disclosure relates to therapeutic agents, compositions and methods for treating a muscle disease or condition characterized by impaired insulin-dependent signaling by targeting components of the defective insulin signaling pathway. The disease or condition may be treated by administering a therapeutic agent that activates the insulin signaling pathway, in particular, therapeutic agents that act post-insulin receptor to modulate intracellular effector molecules. An exemplary modulator is metformin. Metformin may be administered alone or may be coadministered with another therapeutic agent for treating the muscle disease or condition, such as a corticosteroid.

Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating natural surfaces that contain bacterial biofilm, including unexpected synergy or enhancing effects between bismuth-thiol (BT) compounds and certain antibiotics, to provide formulations including antiseptic formulations. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating certain gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating certain gram-negative bacterial infections.

The present invention relates to novel compositions comprising: a fungicide that inhibits mitochondrial respiration at the QoI site (QoI inhibitor), a contact fungicide, a demethylation inhibitor, and pigments, which are highly suitable for controlling unwanted phytopathogenic fungi. Moreover, the fungicidal compositions are able to control mold and fungus infection in grasses and in particular turf grasses.

A method of treating a surface of a substrate using modified urushiol derived from Toxicodendron vernicifluum is provided. More particularly, the reactivity of a hydroxyl group of urushiol extracted from fresh Toxicodendron vernicifluum is removed before the lacquer is used as a UV coating agent for a substrate such as a steel sheet. Therefore, the substrate may have high antibacterial activity, and excellent appearance and functionalities such as far-infrared radiation, blocking of electromagnetic waves, enhanced corrosion resistance, high crosslinking speed when a low content of a photoinitiator is used, excellent surface gloss and high scratch resistance.

This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemotherapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomicin C, imatinib, iressa and velcade (vortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics.

A process for treating offshore natural gas includes processing the natural gas on an off-shore processing facility by, (i) liquefying and fractionating the natural gas to generate a liquefied natural gas stream and a higher hydrocarbon stream, (ii) vaporizing at least a portion of the higher hydrocarbon stream, (iii) passing the vaporized higher hydrocarbon stream and steam over a steam reforming catalyst to generate a reformed gas mixture comprising methane, steam, carbon oxides and hydrogen, (iv) passing the reformed gas mixture over a methanation catalyst to generate a methane rich gas, and (v) combining the methane-rich gas with the natural gas prior to the liquefaction step.

The portable, wearable, proximal Alzheimer's disease treatment invention is based upon creating an RF field of particular frequencies and intensities that are applied to the patient's head. To accomplish the aforementioned disease treatment functionality, a system was invented comprising a network of antennas connected to an RF generator via a feedline connector. The invention also provides methods for using measurements to monitor and manage the effectiveness of an ongoing disease treatment regimen, and databases which contain information about measurements, variables, and their relationships to clinical outcome.

Embodiments of the present invention include an apparatus and method for treatment of pain by a device that provides transcutaneous electrical nerve stimulation. The device includes an applicator equipped with an electric pulse provider that sends an electric pulse to a set of electrodes disposed in an applicator head. The device is placed onto the skin of a patient's body at the point where the patient experiences pain and such that the electrodes of the device contact the skin of the patient while an insulating land area between the electrodes compresses the nerve during transmittal of the electric pulse through the electrodes and into the patient's body.

A system and method for treatment of skin including a treatment surface having numerous small energy emitting points for fractional skin treatment as well as negative pressure outlets. During a treatment, negative pressure from the outlets may exert a pulling force on an opposing tissue surface to bring the tissue into contact with the energy points.

Cells that are in the process division are vulnerable to damage by AC electric fields that have specific frequency and field strength characteristics. The selective destruction of rapidly dividing cells can therefore be accomplished by imposing an AC electric field in a target region for extended periods of time at particular frequencies with particular filed strengths. Some of the cells that divide while the field is applied will be damaged, but the cells that do not divide will not be harmed. This selectively damages rapidly dividing cells like bacteria, but does not harm normal cells that are not dividing. Since the vulnerability of the dividing cells is strongly related to the alignment between the long axis of the dividing cells and the lines of force of the electric field, improved results can be obtained when the field is sequentially imposed in different directions.

Methods and devices for cardiac signal analysis in implantable cardiac therapy systems. Several signal processing and/or conditioning methods are shown including R-wave detection embodiments including the use of thresholds related to previous peak amplitudes. Also, some embodiments include sample thresholding to remove extraneous data from sampled signals. Some embodiments include weighting certain samples more heavily than other samples within a sampled cardiac signal for analysis.

A method and system of conditioning human skin and hair using a hand-held skin/hair conditioner having interchangeable interface conductors that are contoured to enhance electrical conductivity between the conditioner and a variety of body areas. Each of the interchangeable interface conductors are preferably formed to maximize surface area contact with a variety of body surfaces such as scalp/hair, body skin, and facial skin. In a preferred embodiment, the skin/hair conditioner is formed to fit comfortably and controllably in a user's grasp while providing maximum contact with the selected body surface. The skin/hair conditioner includes an audio signal generator and a vibration mechanism to alert a user of a change in status of the conditioner. The interface conductors may be (1) smoothly rounded, (2) include teeth, (3) spherical or hemispherical (4) include multiple rounded nodules. The housings for the conditioner may be (1) elongated and somewhat flattened, (2) of elongated cylindrical shape, or (3) of a compact configuration similar to a door knob. The interface conductors and conditioning system may have a releasable latch, and spring arrangements for ejecting the interface conductor when the latch is released.

Non-invasive electrical nerve stimulation devices and magnetic stimulation devices are disclosed, along with methods of treating medical disorders using energy that is delivered noninvasively by such devices. The disorders comprise migraine and other primary headaches such as cluster headaches, including sinus symptoms that resemble an immune-mediated response (“sinus” headaches), irrespective of whether those symptoms arise from an allergy that is co-morbid with the headache. The disclosed methods may also be used to treat other disorders that may be co-morbid with migraine headaches, such as anxiety disorders. In preferred embodiments of the disclosed methods, one or both of the patient's vagus nerves are stimulated non-invasively. In other embodiments, parts of the sympathetic nervous system and/or the adrenal glands are stimulated.

There is provided an ultrasonic cancer treatment enhancer and cell killer that can significantly improve the effect of treating cancer by ultrasonic irradiation while ensuring a high level of safety. The ultrasonic cancer treatment enhancer and cell killer comprise metal semiconductor particles and can be activated upon ultrasonic irradiation to kill or destruct cancer cells.

An ultrasound medical treatment system includes an end effector insertable into a patient. The end effector includes a tissue-retaining device. The tissue-retaining device includes a first tissue-retaining member having an ultrasound medical-treatment transducer and includes a second tissue-retaining member. The first and second tissue-retaining members are operatively connected together to retain patient tissue between the first and second tissue-retaining members and to release patient tissue so retained. In one example, the second tissue-retaining member has an ultrasound reflector. In the same or a different example, the ultrasound medical-treatment transducer is an ultrasound imaging and medical-treatment transducer.

Devices, systems and methods are described which control blood pressure and nervous system activity by stimulating baroreceptors. By selectively and controllably activating baroreceptors and/or nerves, the present invention reduces blood pressure and alters the sympathetic nervous system; thereby minimizing deleterious effects on the heart, vasculature and other organs and tissues. A baroreceptor activation device or other sensory activation device is positioned near a dermal bone to provide the treatment.

An exemplary system for generating a counter-stimulation in a patient suffering from RLS includes a device configured and arranged to generate a counter-stimulation in a patient suffering from RLS, the counter-stimulation of an amplitude, intensity, and time duration lower than that which would wake the patient and higher than that sufficient to relieve RLS, or sufficient to relieve RLS symptoms and allow the patient to return to sleep, a controller configured and arranged to drive the counter-stimulation generation device, the controller being in communication with the counter-stimulation device, and a base configured and arranged to hold the counter-stimulation generation device adjacent to a patient, the counter-stimulation device attached to the base. An exemplary method of treating RLS includes selecting a patient experiencing RLS, and stimulating a portion of the patient at an amplitude, intensity, and duration sufficient to act as a counter-stimulation to RLS.

A device for directing a liquid onto a plurality of surfaces of the oral cavity, the device including a handle, a neck, and a head, where the head includes a cleaning component including a chamber for maintaining the liquid proximate the surfaces, where the chamber is defined by front and rear sealing membranes, inner side walls and a base inner wall, and where the inner side walls each include a plurality of openings, the device further including a first manifold and a second manifold, and a first port and a second port for conveying liquid.

A device for directing a liquid onto a plurality of surfaces of the oral cavity, the device including a handle, a neck, and a head, where the head includes a cleaning component including a chamber for maintaining the liquid proximate the surfaces, where the chamber is defined by front and rear sealing membranes, inner side walls and a base inner wall, and where the inner side walls each include a plurality of openings, the device further including a first manifold and a second manifold, and a first port and a second port for conveying liquid.

A burner for an exhaust aftertreatment system may include a housing assembly and an ignition device. The housing assembly may include an inner shell surrounded by intermediate and outer shells. The inner shell may at least partially define a combustion chamber. The housing assembly may include an airflow passage having an opening extending through the outer shell. The airflow passage may extend between the outer shell and the intermediate shell as well as between the intermediate shell and the inner shell. The airflow passage may provide fluid communication between the opening and the combustion chamber. The ignition device may be at least partially disposed within the housing assembly and may ignite fuel received from a fuel source and air received from the airflow passage to produce a flame in the combustion chamber. The airflow passage may be in a heat transfer relationship with the flame in the combustion chamber.

This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.

A treatment element to treat material in a multi-shaft worm machine has an outer contour with at least one outer contour portion, the associated evolute of which is a quantity of at least three points, each of the points lying outside the longitudinal axis and within the outer radius of the treatment element and two respective adjacent points having a spacing from one another, which is less than half the core radius. The treatment element ensures high flexibility during the adjustment of shear and/or extensional flows on the material to be treated.

The present invention discloses a high intensity ultrasonic treatment method and apparatus that is used in conjunction with an existing commercial dough or batter mixer to enhance the rheological, aeration and textural properties of the dough or batter. This change in properties is a result of the phenomenon of acoustic cavitation induced in the dough or batter by treatment with high intensity ultrasonic waves. The present invention discloses a mixing bowl (20) of an existing mixer system that is preloaded with dough or batter, the bowl (20) is located at the center of an ultrasonic bath tank (101) filled with a working fluid. The effect of ultra-sonic waves with power levels above 1 kW can be observed over the entire or partial mixing period of the dough or batter. The ultra-sonic waves of the present invention are generated by a plurality of ultrasonic wave generators (104A, 104B) and piezoelectric transducers (1) mounted on a stainless steel tank (101). The electrical energy received in each transducer (1) will be converted into appropriate mechanical expansion and contractions in the piezoelectric ceramics of the transducer (1) thus leading to pressure waves being transmitted to the dough or batter to be mixed. The generation and transmission of high intensity ultrasonic waves to the dough or batter affects its rheological, aeration and textural properties.

The present invention relates to the use of selective adenosine A1 agonists, in particular the dicyanopyridines of formula (I), for the treatment and/or prophylaxis of glaucoma and ocular hypertension as well as the their use for the production of a medicament for the treatment and/or prophylaxis of glaucoma and ocular hypertension.

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.

Provided is a catalyst article for simultaneously remediating the nitrogen oxides (NOx), particulate matter, and gaseous hydrocarbons present in diesel engine exhaust streams. The catalyst article has a soot filter coated with a material effective in the Selective Catalytic Reduction (SCR) of NOx by a reductant, e.g., ammonia.

Provided is a catalyst article for simultaneously remediating the nitrogen oxides (NOx), particulate matter, and gaseous hydrocarbons present in diesel engine exhaust streams. The catalyst article has a soot filter coated with a material effective in the Selective Catalytic Reduction (SCR) of NOx by a reductant, e.g., ammonia.

Provided is a catalyst article for simultaneously remediating the nitrogen oxides (NOx), particulate matter, and gaseous hydrocarbons present in diesel engine exhaust streams. The catalyst article has a soot filter coated with a material effective in the Selective Catalytic Reduction (SCR) of NOx by a reductant, e.g., ammonia.

Provided are emissions treatment systems for an exhaust stream having an ammonia-generating component, such as a NOx storage reduction (NSR) catalyst or a lean NOx trap (LNT) catalyst, and an SCR catalyst disposed downstream of the ammonia-generating catalyst. The SCR catalyst can be a molecular sieve having the CHA crystal structure, for example SSZ-13 or SAPO-34, which can be ion-exchanged with copper. The LNT can be layered, having an undercoat washcoat layer comprising a support material, at least one precious metal, and at least one NOx sorbent selected from the group consisting of alkaline earth elements, rare earth elements, and combinations thereof and a top washcoat layer comprising a support material, at least one precious metal, and ceria in particulate form, the top washcoat layer being substantially free of alkaline earth components. The emissions treatment system is advantageously used for the treatment of exhaust streams from diesel engines and lean burn gasoline engines.

A device and method for using the device arranged to maintain anatomical alignment between a joint by creating a dynamic load around the joint to restore and maintain the anatomical alignment. The orthotic device uses a hinge to create a directed force on a tibia by maintaining misalignment of an instant center of rotation (ICoR) of the hinge at a position relative to an anatomical knee joint.